

## American College of Radiology ACR Appropriateness Criteria®

**Clinical Condition:**                      **Bone Tumors**

**Variant 1:**                                      **Screening, first study.**

Radiologic Procedure	Rating	Comments	RRL*
X-ray area of interest	9	Absolute requirement in patient with suspected bone lesion.	NS
US area of interest	1	Not indicated as initial study.	None
MRI area of interest	1		None
NUC bone scan targeted	1		Med
CT area of interest	1	Not indicated as initial study.	NS
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

**Variant 2:**                                      **Persistent symptoms, but radiograph negative.**

Radiologic Procedure	Rating	Comments	RRL*
MRI area of interest	9	Contrast may be useful, depends on expertise and institutional preference.	None
NUC bone scan targeted	4	Good option if patient cannot have MRI. Non specific, MRI more specific and sensitive.	Med
CT area of interest without contrast	3	If MRI not available. Useful to evaluate cortex and trabecular pattern.	NS
US area of interest	1		None
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

**Variant 3:**                                      **Definitively benign on radiographs (Excluding Osteoid Osteoma).**

Radiologic Procedure	Rating	Comments	RRL*
US area of interest	1		None
MRI area of interest	1		None
CT area of interest	1		NS
NUC bone scan targeted	1		Med
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

**Clinical Condition:****Bone Tumors****Variant 4:****Clinically suspected osteoid osteoma.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
CT area of interest without contrast	9	Contrast not needed.	NS
X-ray area of interest	9	Necessary. Follow with CT if positive.	NS
NUC bone scan targeted	6	Very sensitive but non-specific. Good for localization if lesion is occult radiographically.	Med
MRI area of interest	6	CT is more useful but diagnosis can often be made with MRI. Contrast may improve nidus identification.	None
CT area of interest without and with contrast	2		NS
US area of interest	1		None
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

**Variant 5:****Suspicious for malignant characteristics on radiograph.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b>RRL*</b>
MRI area of interest	9	Contrast can provide more information. Useful for vascularity and necrotic areas.	None
CT area of interest without and with contrast	5	May be useful if MRI not available or possible. Useful for evaluation of calcification, cortical breakthrough and pathological fractures.	NS
FDG-PET area of interest	3	Can be useful for problem solving.	High
NUC bone scan targeted	3	Probably not indicated, except to look for additional lesions.	Med
US area of interest	1		None
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

## BONE TUMORS

Expert Panel on Musculoskeletal Imaging: William B. Morrison, MD<sup>1</sup>; Murray K. Dalinka, MD<sup>2</sup>; Richard H. Daffner, MD<sup>3</sup>; Arthur A. De Smet, MD<sup>4</sup>; George Y. El-Khoury, MD<sup>5</sup>; John B. Kneeland, MD<sup>6</sup>; B.J. Manaster, MD, PhD<sup>7</sup>; Helene Pavlov, MD<sup>8</sup>; David A. Rubin, MD<sup>9</sup>; Robert Schneider, MD<sup>10</sup>; Lynne S. Steinbach, MD<sup>11</sup>; Barbara N. Weissman, MD<sup>12</sup>; Robert H. Haralson III, MD.<sup>13</sup>

### **Summary of Literature Review**

There are numerous imaging techniques for evaluating bone tumors. However, the routine radiograph remains the primary screening technique and is the least expensive for detection and histologic characterization of many tumor or tumor like conditions of bone [1]. When a classically benign-appearing lesion is detected on routine radiographs, additional studies may not be required unless surgical intervention is contemplated and further anatomic information is required. In this setting either computed tomography (CT) or magnetic resonance imaging (MRI) may be most appropriate for preoperative evaluation [1-3].

When routine radiographic features are indeterminate or the lesion is more aggressive and considered to be potentially malignant, additional imaging studies are frequently required. In the past, radionuclide imaging was used to evaluate bone lesions in this setting. However, today, because of MRI's improved anatomic detail and sensitivity, it is preferred over radionuclide studies [4]. Early evaluation of MRI and CT demonstrated that MRI was superior for staging of bone tumors before treatment [1,3,5,6]. Zimmer et al [3] and Hogeboom et al [5] described MR and CT features of bone tumors with regard to cortical destruction, marrow, soft-tissue, joint and neurovascular involvement. Hogeboom et al [5] reported MRI was superior to CT for cortical bone destruction in 4.5%, for marrow involvement in 25%, for soft tissue involvement in 31%, for joint involvement in 36.4%, and for invasion of neurovascular structures in 15.3% of patients studied. In the same categories MRI and CT were felt to be equal in 63%-82% of patients. CT was superior to MRI for cortical bone destruction in 13.6% of patients and neurovascular involvement in 7.7%

of patients [5]. In most institutions the choice of imaging technique depends on patient status as well as the location and type of suspected lesion. MRI is most typically used for staging lesions in the extremities [1,3,6-8]. MR spectroscopy has potential to differentiate benign from malignant lesions, but more research is needed [9]. CT is usually preferred when tumors are located within the periosteal or cortical regions, with flat bones with thin cortex and little marrow, and to better demonstrate tumor mineralization, which may be suspected from routine radiographs [10]. For rib lesions, thin-section CT is useful to exclude benign fracture [11]. CT is also preferred over MRI for detecting a characteristic central nidus in patients with suspected osteoid osteoma on radiographs [1,2,12,13]. Positron emission tomography (PET) scanning has potential to differentiate metabolically active bone lesions from indolent ones [14,15], but this modality has mainly been used to detect metabolically active metastatic lesions or recurrences, or for preoperative evaluation of known sarcomas.

There are special considerations when dealing with suspected chondroid lesions. Intramedullary chondroid lesions appearing in the hands and feet are nearly always benign, and may present incidentally or as a pathological fracture. If the lesion is elsewhere it may be challenging by any imaging modality to differentiate a benign lesion from a low-grade malignancy. If there is pain related to the lesion, suspicion of malignancy should be high. Murphey et al [16] suggest that imaging features including deep endosteal scalloping, cortical destruction, soft tissue mass (on CT or MRI), periosteal reaction (on radiographs) and marked uptake of radionuclide can be used to distinguish appendicular enchondroma from chondrosarcoma in at least 90% of cases. Geirnaerd et al [17] suggest that radiographic signs cannot discriminate reliably between enchondroma and grade 1 chondrosarcoma, but that axial location and large size (greater than 5 cm) are the most reliable predictors of malignancy in this setting. Geirnaerd et al [18] suggest that dynamic contrast-enhanced MRI can assist in differentiating benign from malignant chondroid lesions, and Feldman et al [19] suggest that PET may be useful; however, these modalities have not been clearly established for this purpose. Protocol for follow-up of an asymptomatic, incidentally identified lesion has not been scientifically established. Authors such as Mirra's group [20] suggest that risk of malignant transformation is increased for larger lesions, lesions in the axial skeleton, and in the setting of multiple lesions (e.g., Ollier's disease) and suggest radiographic follow-up for those with higher risk but stop short of making specific recommendations regarding interval and extent of follow-up.

<sup>1</sup>Review Author, Thomas Jefferson University Hospital, Philadelphia, Pa; <sup>2</sup>Panel Chair, University of Pennsylvania Hospital, Philadelphia, Pa; <sup>3</sup>Allegheny General Hospital, Pittsburgh, Pa; <sup>4</sup>University of Wisconsin, Madison, Wis; <sup>5</sup>University of Iowa Hospitals and Clinics, Iowa City, Iowa; <sup>6</sup>University of Pennsylvania Hospital, Philadelphia, Pa; <sup>7</sup>University of Colorado Health Science Center, Denver, Colo; <sup>8</sup>Hospital for Special Surgery, New York, NY; <sup>9</sup>Washington University of St. Louis, St. Louis, Mo; <sup>10</sup>Hospital for Special Surgery, New York, NY; <sup>11</sup>University of California, San Francisco, Calif; <sup>12</sup>Brigham & Women's Hospital, Boston, Mass; <sup>13</sup>American Academy of Orthopaedic Surgeons, Chicago, Ill.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Patients with symptoms related to the bone or joint with normal radiographs present a different problem. Though CT may be performed in this setting, a radionuclide bone scan may be more useful to localize the abnormality [2,12]. MRI can be very useful in this setting not only to identify whether a lesion is present but also to define the nature of a lesion based on the features discussed above; as a result, MRI is generally preferred. If an osteoid osteoma is suspected, Assoun et al [2] reported that CT was more accurate than MRI in 63% of cases. However, Liu et al [21] reported that dynamic contrast-enhanced MRI can improve conspicuity of osteoid osteoma compared to CT.

Other invasive imaging techniques, such as angiography, are not commonly required. Weatherall et al [22] compared MRI, CT, technetium-99m bone scans, and angiography for local staging of 56 patients with primary bone sarcomas. This study demonstrated that MRI was superior to CT and scintigraphy in defining the extent of bone involvement and was equal in accuracy to CT in demonstrating joint and cortical involvement. CT, MR, and angiography were compared for evaluating neurovascular involvement. CT demonstrated a sensitivity of 33%, MR 100%, and angiography 83% with specificities of 93% for CT, 98% for MR, and 71% for angiography. This study concluded that MR was the technique of choice for evaluating and staging primary bone sarcomas, including neurovascular involvement. MRI is useful for determining tissue characteristics of a bone lesion, such as fat, hemorrhage, fibrous tissue or fluid levels; with gadolinium contrast, cystic or necrotic areas can be detected [8,23-25].

### Anticipated Exceptions

Routine radiographs remain the optimal screening technique. When lesions are characteristically benign, additional imaging may not be required unless needed for preoperative planning. The above data suggest that MRI is the preferred technique for staging of primary bone neoplasms but in some categories CT is equal or superior to MRI. CT is preferred for patients with suspected osteoid osteoma or subtle cortical abnormalities, and for evaluating lesion calcification or tumor matrix.

Additional exceptions for utilization of MRI include patient size and clinical status and the presence of certain metallic or electrical implants that may preclude the use of MRI.

### References

1. Sundaram M, McLeod RA. MRI of tumor and tumor like lesions of bone and soft tissue. *AJR* 1990; 155(4):817-824.
2. Assoun J, Richardi G, Railhac JJ, et al. Osteoid osteoma: MRI versus CT. *Radiology* 1994; 191(1):217-223.
3. Zimmer WD, Berquist TH, McLeod RA, et al. Bone tumors: Magnetic Resonance Imaging versus CT. *Radiology* 1985; 155(3):709-718.

4. Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs. scintigraphy. *AJR* 1990; 155(5):1043-1048.
5. Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. MRI or CT in the preoperative diagnosis of bone tumors. *Eur J Surg Oncol* 1992; 18(1):67-72.
6. Bloem JL, Taminiau AH, Eulderink F, et al. Radiologic staging of primary bone sarcoma: MRI, scintigraphy, angiography and CT correlated with pathologic examination. *Radiology* 1988; 169(3):805-810.
7. Griffiths HJ, Galloway HR, Thompson RC Jr, et al. The use of MRI in the diagnosis of benign and malignant bone and soft tissue tumours. *Australas Radiol* 1993; 37(1):35-39.
8. Seeger LL, Widoff BE, Bassett LW, et al. Preoperative evaluation of osteosarcoma: value of gadopentetate dimeglumine-enhanced MRI. *AJR* 1991; 157(2):347-335.
9. Wang CK, Li CW, Hsieh TJ, et al. Characterization of bone and soft-tissue tumors with in vivo <sup>1</sup>H MR spectroscopy: initial results. *Radiology* 2004; 232(2):599-605.
10. Collins MS, Koyama T, Swee RG, Inwards CY. Clear cell chondrosarcoma: radiographic, computed tomographic and magnetic resonance findings in 34 patients with pathologic correlation. *Skeletal Radiol* 2003; 32(12):687-694.
11. Niitsu M, Takeda T. Solitary hot spots in the ribs on bone scan: value of thin-section reformatted computed tomography to exclude radiography-negative fractures. *JCAT* 2003; 27(4):469-474.
12. Klein MH, Shankman S. Osteoid osteoma: radiologic and pathologic correlation. *Skeletal Radiol* 1992; 21(1):23-31.
13. Davies M, Cassar-Pullicino VN, Davies AM, et al. The diagnostic accuracy of MR imaging in osteoid osteoma. *Skeletal Radiol* 2002; 31(10):559-569.
14. Lee FY, Yu J, Chang SS, et al. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. *J Bone Joint Surg Am* 2004; 86-A(12):2677-2685.
15. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. *Radiology* 2001; 219(3):774-777.
16. Murphey MD, Flemming DJ, Boyea SR, et al. Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features. *Radiographics* 1998; 18(5):1213-1237.
17. Geirnaerd MJ, Hermans J, Bloem JL, et al. Usefulness of radiography in differentiating enchondroma from central grade I chondrosarcoma. *AJR* 1997; 169(4):1097-1104.
18. Geirnaerd MJ, Hogendoorn PC, Bloem JL, et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. *Radiology* 2000; 214(2):539-546.
19. Feldman F, Van Heertum R, Saxena C, Parisien M. <sup>18</sup>F-FDG-PET applications for cartilage neoplasms. *Skeletal Radiol* 2005; 34(7):367-374.
20. Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. *Skeletal Radiol* 1997; 26(6):325-353.
21. Liu PT, Chivers FS, Roberts CC, et al. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. *Radiology* 2003; 227(3):691-700.
22. Weatherall PT, Maale GE, Mendelsohn DB, et al. Chondroblastoma: classic and confusing appearance at MRI. *Radiology* 1994; 190(2):467-474.
23. Campbell RS, Grainger AJ, Mangham DC, et al. Intraosseous lipoma: report of 35 new cases and a review of the literature. *Skeletal Radiol* 2003; 32(4):209-222.
24. Murphey MD, wan Jaovisidha S, Temple HT, et al. Telangiectatic osteosarcoma: radiologic-pathologic comparison. *Radiology* 2003; 229(2):545-553.
25. Frick MA, Sundaram M, Unni KK, et al. Imaging findings in desmoplastic fibroma of bone: distinctive T2 characteristics. *AJR* 2005; 184(6):1762-1767.

An ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.